Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The In vitro activity of carbapenems alone and in combination with β-lactamase inhibitors against difficult-to-treat mycobacteria; Mycobacterium tuberculosis, Mycobacterium abscessus, and Mycobacterium avium complex: A systematic review.
Andersson V, Fröberg G, Dahl VN, Chryssanthou E, Giske C, Schön T, Forsman LD. Andersson V, et al. Among authors: schon t. Int J Mycobacteriol. 2023 Jul-Sep;12(3):211-225. doi: 10.4103/ijmy.ijmy_131_23. Int J Mycobacteriol. 2023. PMID: 37721224 Free article. Review.
Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.
Juréen P, Angeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T. Juréen P, et al. Among authors: schon t. J Clin Microbiol. 2010 May;48(5):1853-8. doi: 10.1128/JCM.00240-10. Epub 2010 Mar 17. J Clin Microbiol. 2010. PMID: 20237102 Free PMC article.
Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T. Angeby KA, et al. Among authors: schon t. J Antimicrob Chemother. 2010 May;65(5):946-52. doi: 10.1093/jac/dkq091. Epub 2010 Mar 23. J Antimicrob Chemother. 2010. PMID: 20332195
Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L, Schön T, Simonsson US, Bruchfeld J, Larsson M, Juréen P, Sturegård E, Giske CG, Ängeby K. Davies Forsman L, et al. Among authors: schon t. Antimicrob Agents Chemother. 2014 Dec;58(12):7557-9. doi: 10.1128/AAC.02995-14. Epub 2014 Sep 22. Antimicrob Agents Chemother. 2014. PMID: 25246405 Free PMC article.
Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.
Sturegård E, Ängeby KA, Werngren J, Juréen P, Kronvall G, Giske CG, Kahlmeter G, Schön T. Sturegård E, et al. Among authors: schon t. Clin Microbiol Infect. 2015 Feb;21(2):148.e5-7. doi: 10.1016/j.cmi.2014.08.021. Epub 2014 Oct 29. Clin Microbiol Infect. 2015. PMID: 25640156 Free article.
Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T. Niward K, et al. Among authors: schon t. J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3. J Antimicrob Chemother. 2016. PMID: 26538509
182 results